Good morning everyone, and welcome to Thursday, 16 November \u2013 a date on the Great Musical Calendar that will forever be remembered as the day the world was nearly permanently spared the insufferable presence of U2 frontman Bono, following a \u201chigh energy bicycle accident\u201d in 2014.<\/p>\n
Sadly for most people, Bono not only survived being toppled from his bicycle but went on to deliver even more earnest torment on those around the globe, including this memorable moment when he and The Edge decided that playing a secret gig together from the safety of the bottom of a Ukraine train station escalator would bring an end to hostilities with Russia.<\/p>\n
\u00a0<\/p>\n\n
\u00a0<\/p>\n
Spoiler alert: it didn\u2019t.<\/p>\n
The lesson here is pretty clear \u2013\u00a0\u201dLet\u2019s go there and sing\u201d isn\u2019t really an appropriate response to an unfolding humanitarian crisis, lads. Next time, stay home and say dumb things on X, like a normal person.<\/p>\n
Anyway\u2026 to prep you for the day ahead, we\u2019ve got a bunch of great stories from our dedicated Stockhead team, none of whom have ever decided to hold an impromptu performance in an underground train station to send a message to Vladimir Putin.<\/p>\n
Those stories include Josh Chiat\u2019s excellent coverage of Argonaut\u2019s list of best ASX undeveloped projects<\/a>, and Eddy Sunarto\u2019s top-medicine cabinet drawer look at stuff that happened in biotechs over the past fortnight<\/a>.<\/p>\n Christian Edwards squeezed three stocks picks out of Kyle Rodda that seem pretty solid in these yield-flipping times<\/a>.<\/p>\n Plus, as always, here\u2019s all the fiddly data and digits to get you up to speed this morning as well.<\/p>\n \u00a0<\/p>\n Gold: US$1,967.55 (+0.20%)<\/p>\n Silver: US$23.20 (+0.35%)<\/p>\n Nickel (3mth): US$16,996.14\/t (-0.02%)<\/p>\n Copper (3mth): US$8,080.50\/t (-0.01%)<\/p>\n Oil (WTI): US$78.55 (+0.45%)<\/p>\n Oil (Brent): US$82.83 (+0.45%)<\/p>\n Iron 62pc Fe: US$128.34\/t (+0.21%)<\/p>\n AUD\/USD: 0.6501 (+0.01%)<\/p>\n Bitcoin: US$35,575 (+0.06%)<\/p>\n \u00a0<\/p>\n Everyone\u2019s gone a bit Resources mad the past few days, and this excellent snapshot certainly grabbed us by the socials yesterday.<\/p>\n \u00a0<\/p>\n Errawarra flies as Azure & Raiden money drips to Andover lithium neighbours \u2014 Stockhead (@StockheadAU) November 15, 2023<\/a><\/p>\n\n \u00a0<\/p>\n Here are the best performing ASX small cap stocks:<\/p>\n Swipe or scroll to reveal full table. Click headings to sort:<\/p>\n WordPress Tables Plugin<\/a><\/p>\n \u00a0<\/p>\n Yesterday\u2019s Small Caps highlights were:<\/p>\n Up enormously \u2013 but off one of the biggest collapses in 2023 \u2013 it looks like Firebrick Pharma (ASX:FRE)<\/a> has had a reprieve. And a good one at that.<\/p>\n Firebrick has been developing and commercialising a povidone-iodine nasal spray called Nasodine with all the international trademarks and patents \u2013 some of which have already been granted in the US, Europe and here.<\/p>\n There\u2019s been six clinical trials to date for Nasodine, including a Phase 1 study, three Phase 2 studies and two Phase 3 studies, which have affirmed the product\u2019s But\u2026 Firebrick has been continuing its investigation into the results of the 2022-2023 Phase 3 common cold trial (2023 Trial), which in short, it reckons was a dud.<\/p>\n Now an indie expert agrees:<\/p>\n \u201cThe model outcomes strongly indicate major inaccuracies in the 2023 trial data, casting doubt on its reliability. This raises significant concerns about using the 2023 So maybe the spray does cure the common cold after all\u2026<\/p>\n Findi (ASX:FND)<\/a> was up over 100% early and while buying calmed some in the sharp light of arvo, the gains were still impressive.<\/p>\n Everything you need to know about FND is in this rather timely peice of journalism Eddy wrote till the wee hours and filed just before the open<\/a>. What a legend. What a gun. What a shame he\u2019s too skint to put ten quid on the nose.<\/p>\n \u2026 because yesterday morning FND dropped the news that its Indian subsidiary, Transaction Solutions International, had raised circa $38 million via placement ahead of its groundbreaking Indian IPO this week.<\/p>\n That money has come via leading Indian investment group, Piramal Alternatives, by way of Compulsory Convertible Debenture which are compulsorily convertible to equity at IPO.<\/p>\n \u201cThe entry equity valuation is based on an FY23 EBITDA multiple and reflects a pre-IPO market capitalisation of $153.0 million (post money $190.6 million) ahead of TSI India\u2019s intended listing on the Bombay Stock Exchange,\u201d Findi says.<\/p>\n Also up: lots of little ASX lithium miners.<\/p>\n \u00a0<\/p>\n Here are the worst performing ASX small cap stocks:<\/p>\n Swipe or scroll to reveal full table. Click headings to sort:<\/p>\n WordPress Tables Plugin<\/a><\/p>\n \u00a0<\/p>\n Karoon Energy (ASX:KAR)<\/a> \u2013 Pending an announcement regarding a potential transaction<\/p>\n Mithril Resources (ASX:MTH)<\/a> \u2013 Pending an announcement in connection to the scheme of arrangement with Newrange Gold<\/p>\n Mako Gold (ASX:MKG)<\/a> \u2013 Pending an announcement regarding a capital raising<\/p>\n Virdis Mining and Minerals (ASX:VNM)<\/a> \u2013 Pending the release of an announcement in relation to drill assay results from the Company\u2019s Colossus project<\/p>\n Panoramic Resources (ASX:PAN)<\/a> \u2013 Pending an update on financial, strategic and operational matters<\/p>\n Asra Minerals (ASX:ASR)<\/a> \u2013 Pending the release of an announcement in relation to a capital raising<\/p>\n \u00a0<\/p>\n <\/span><\/p>\n The post Rise and Shine: Everything you need to know before the ASX opens-330<\/a> appeared first on Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"COMMODITY\/FOREX\/CRYPTO MARKET PRICES<\/h2>\n
WHAT GOT YOU TALKING<\/h2>\n
\n Odessa surges on Yinnetharra #lithium<\/a> targeting as Osmond announces Spanish SOP, alumina & graphite deal
\n Atlantic Lithium runs after rejecting Assore takeover offer https:\/\/t.co\/aXHPgIYddi<\/a><\/p>\nYESTERDAY\u2019S ASX SMALL CAP LEADERS<\/h2>\n
\nsafety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of uses.<\/p>\n
\ndata to draw conclusions about the efficacy of the active versus placebo in that trial.\u201d<\/p>\nYESTERDAY\u2019S ASX SMALL CAP LAGGARDS<\/h2>\n
TRADING HALTS<\/h2>\n